Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.7352W HIGH $9.54
Volume
33.95 K
Value Traded
3.87 M
Short % Float
10.59%
+6.81%Week
-9.65%1 Month
-4.9%3 Month
-4.34%6 Month
-46.1%5 Year
-46.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
681.34 M
EPS (TTM)
-1.26
P/E Ratio
-
Ent. Value
350.76 M
Total Shares
103.70 M
Float Shares
66.56 M
Insiders
35.82%
Institutions
62.79%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AURA Catalyst Timeline
Dated clinical, regulatory and corporate events for Aura Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aura Biosciences, Inc.
204Total events
2Upcoming
29Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteBel-sarTrial
Phase 3 CoMpass trial fully enrolled with 108 patients
ocular oncologysource ↗
●Pipeline PrioritizationBel-sarCorporate
Strategic operating plan refined to focus on bel-sar in ocular oncology
ocular oncologysource ↗
▲Interim Efficacy DataBel-sarClinical Data
Interim NMIBC data reinforce bel-sar's potential for durable efficacy and favorable safety
non-muscle invasive bladder cancersource ↗
▲Enrollment CompleteBel-sarTrial
Enrollment complete in Phase 3 CoMpass trial
early choroidal melanomasource ↗
▲Enrollment CompleteBel-sarTrial
Enrollment completed in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma
early choroidal melanomasource ↗
◆Topline ReadoutBel-sarClinical Data
Initial three-month clinical data expected mid-2026
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Oral PresentationPresentation
TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
▼Equity OfferingCorporate
Closing of $299 million public offering including full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of $260 million public offering of common stock and pre-funded warrants
◆Enrollment UpdateBel-sarTrial
86 patients enrolled; over 25 additional patients scheduled or identified for screening through May 2026
early choroidal melanomasource ↗
◆Management ChangeCorporate
Natalie Holles appointed CEO and President, effective April 30, 2026
◆Enrollment CompleteBel-sarTrial
Enrollment completion expected by mid-2026
early choroidal melanomasource ↗
▲Manufacturing MilestoneBel-sarCMC / Inspection
Achieved 12-month stability of new formulation for non-ocular solid tumors
non-ocular solid tumorssource ↗
◆Oral PresentationPresentation
Participation in upcoming investor conferences with fireside chats
▲Runway Guidance UpdateCorporate
Cash runway guidance: operations funded into second half of 2026
◆Topline ReadoutBel-sarClinical Data
Initial efficacy data at 3 months from Phase 1b/2 trial in NMIBC expected by year-end 2025
Non-Muscle-Invasive Bladder Cancer (NMIBC)source ↗
◆Enrollment CompleteBel-sarTrial
Phase 3 CoMpass trial enrollment may be completed as early as end of 2025
Early-stage choroidal melanomasource ↗
◆Trial InitiationBel-sarTrial
Plan to initiate Phase 1 trial in cancers of the ocular surface in 2025
Cancers of the ocular surfacesource ↗
◆Oral PresentationPresentation
Participation in 8th Annual Evercore Healthcare Conference fireside chat
◆Enrollment CompleteBel-sarTrial
Phase 3 enrollment complete as early as end of 2025
primary uveal melanomasource ↗
▲First Patient DosedBel-sarTrial
First patient dosed in Phase 2 trial for metastases to the choroid
metastases to the choroidsource ↗
▲Oral PresentationBel-sarPresentation
Phase 1 immune profiling data presented at SIU 2025
non-muscle invasive bladder cancer (NMIBC)source ↗
◆Enrollment CompleteBel-sarTrial
Enrollment completion expected as early as end of 2025
early choroidal melanomasource ↗
◆Oral PresentationPresentation
CEO presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Enrollment UpdateBel-sarTrial
Over 240 patients registered in pre-screening tool for CoMpass trial
early choroidal melanomasource ↗
▲Patent GrantedBel-sarIP / Competition
Patent application filed for new formulation of bel-sar for bladder cancer
bladder cancersource ↗
▲Runway Guidance UpdateCorporate
Cash runway guidance: sufficient to fund operations into second half of 2025
▼Equity OfferingCorporate
Launch of underwritten public offering of common stock and warrants
▲First Patient DosedBel-sarTrial
First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in NMIBC
Non-Muscle-Invasive Bladder Cancer (NMIBC)source ↗
◆Management ChangeCorporate
Appointment of Tony Gibney as Chief Financial and Business Officer
◆Oral PresentationPresentation
Participation in upcoming investor conferences with fireside chats
▲Late-BreakerBel-sarPresentation
Late breaker presentation of Phase 1 data at EAU Congress
Non-Muscle-Invasive Bladder Cancer (NMIBC)source ↗
●Oral PresentationBel-sarPresentation
Virtual urologic oncology investor event with KOLs
Non-Muscle-Invasive Bladder Cancer (NMIBC)source ↗
▲Trial CompletionBel-sarTrial
Phase 1 window of opportunity trial completed
Non-Muscle-Invasive Bladder Cancer (NMIBC)source ↗
◆R&D DayBel-sarPresentation
Virtual urologic oncology investor event with key opinion leaders to discuss additional Phase 1 data and program update
non-muscle invasive bladder cancersource ↗
▲Trial InitiationBel-sarTrial
Phase 2 trial initiated in metastases to the choroid
Metastases to the Choroidsource ↗
Past FDA Catalysts and PDUFA Decisions
How AURA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | belzupacap sarotalocan (bel-sar) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$141M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 59%
Micro Cap(rank 389 of 658)
Percentile Rank
Aura Biosciences, Inc. faces pipeline headwinds (33/100), with $352M risk-adjusted pipeline value, led by Bel-sar in Choroidal Melanoma (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bel-sar Small moleculeNCT06007690 | Choroidal Melanoma | Phase 3 | ACTIVE NOT_RECRUITING | 108 | Aug 15, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every AURA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ocular and urologic cancers | Phase 2 | 2025-05-16 | positive data from Phase 2 trials, showing efficacy in targeting tumors and preserving organ functionRead More | May 2025 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bender JeremyDirector | Grant/Award | 30,000 30,000 held | $0.00 | 07/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AURA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 1.6 % | 67.69 M | 9.53 M |
AURA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AURA ranks across every disease it competes in
Competitive Position is a premium feature
See how AURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAURA News
AURAAura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. CEO Natalie Holles will lead a fireside chat, which will be webcast live. The company is focused on developing bel-sar, a novel therapy for ocular cancers, with ongoing clinical studies.
Read more →AURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced the granting of inducement equity awards to new executives, including Dr. Erica Kratz, Dr. Susan Abu-Absi, and Ms. Julie Person. These awards comply with Nasdaq Listing Rule 5635(c)(4) and include stock options and restricted stock units. The company continues to develop its innovative therapy for ocular cancers, with ongoing clinical studies.
Read more →AURAAura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences has successfully enrolled 108 patients in its Phase 3 CoMpass trial, surpassing its enrollment target. The company is on track to release topline data in the second half of 2027. Additionally, interim data for bel-sar in non-muscle invasive bladder cancer (NMIBC) suggest promising efficacy and safety, reinforcing its strategic focus on ocular oncology.
Read more →AURAAura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences has appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender brings extensive experience in biotechnology and oncology, which is expected to enhance Aura's strategic direction as it approaches regulatory approval for its lead candidate, bel-sar. The company is also completing its Phase 3 CoMpass trial for early choroidal melanoma.
Read more →AURAAura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences has completed patient enrollment in its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) aimed at treating early choroidal melanoma. A total of 108 patients were enrolled, and the company expects to report topline data on the primary endpoint in the second half of 2027. This trial marks a critical step towards potential regulatory approval of bel-sar, which aims to be the first approved frontline, vision-preserving therapy for this condition. Aura has also received significant designations from both the FDA and EMA for this treatment.
Read more →AURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 19, 2026
Aura Biosciences has announced inducement equity awards to its new CEO, Natalie Holles, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include stock options, restricted stock units, and performance-based units, with specific vesting schedules. Aura aims to develop precision therapies for solid tumors, highlighting its commitment to innovation in oncology.
Read more →AURAAura Biosciences to Participate in Upcoming May 2026 Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences. The senior management team will engage in fireside chats, which will be available for live streaming and later archived. The company is dedicated to developing therapies for solid tumors, with its lead candidate in late-stage development.
Read more →AURAAura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc. announced that members of its senior management team will participate in key investor conferences in May 2026. The upcoming events include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the TD Cowen 7th Annual Oncology Innovation Summit. The company focuses on precision therapies for solid tumors, with its lead candidate, bel-sar, in late-stage development for early choroidal melanoma. Live webcasts of the presentations will be available on the company's website, allowing for broader investor engagement.
Read more →AURAAura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences reported its financial results for the first quarter of 2026, highlighting significant advancements in its clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma. The trial is nearing completion of patient enrollment and is expected to provide topline data in the second half of 2027. The company also strengthened its financial standing with a $299 million equity financing, which is expected to support operations into mid-2028. Natalie Holles has been appointed as the new CEO, replacing the founder, indicating a shift in leadership.
Read more →AURA▲ +6.6%on this news
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aura Biosciences has successfully closed a public offering, raising approximately $299.4 million. The offering included the sale of over 46 million shares of common stock, with additional pre-funded warrants. This funding will support Aura's ongoing development of precision therapies for solid tumors, including its lead candidate for ocular oncology.
Read more →AURA▲ +19.1%on this newsshared move
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences has appointed Natalie Holles as the new CEO, succeeding founder Elisabet de los Pinos. The company is nearing enrollment completion for its Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) for early choroidal melanoma, with expectations to finalize enrollment by mid-2026 and release topline data in late 2027. Holles brings extensive experience in rare disease commercialization and is poised to lead the company through this critical phase.
Read more →AURA▲ +19.1%on this newsshared move
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences has announced the pricing of a public offering totaling $260 million, which includes shares of common stock and pre-funded warrants. The proceeds will primarily support clinical programs for early choroidal melanoma and other initiatives. The offering is expected to close on May 5, 2026, pending customary conditions.
Read more →AURA▲ +19.1%on this newsshared move
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences has announced a proposed public offering of its common stock and pre-funded warrants. The offering, which is subject to market conditions, aims to raise funds for the company's development of precision therapies for solid tumors. Aura has granted underwriters a 30-day option to purchase additional shares. The final terms will be disclosed in a prospectus supplement filed with the SEC.
Read more →AURAAura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance
Aura Biosciences has reported its financial results for Q4 and the full year of 2025, highlighting significant progress in clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma. Enhanced enrollment anticipates completion by mid-2026, with topline data expected in the second half of 2027. The company has demonstrated stability for a new formulation aimed at non-ocular solid tumors, specifically in urologic oncology. However, financial performance shows a growing net loss, raising questions about future funding sustainability amidst ongoing trial costs.
Read more →AURAAura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in the 8th Annual Evercore Healthcare Conference. CEO Elisabet de los Pinos is scheduled to partake in a fireside chat on December 2, 2025. The discussion will be accessible via a live webcast and will be archived for 90 days. The company continues to focus on developing precision therapies for solid tumors, particularly in late-stage development for early choroidal melanoma.
Read more →AURAAura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported its third quarter 2025 financial results, highlighting progress in its Phase 3 CoMpass trial for early choroidal melanoma and a Phase 1b/2 trial for NMIBC. The company anticipates completing enrollment for the CoMpass trial in 2026, with topline data expected in Q4 2027. Recent immune profiling data supports the potential of bel-sar as a frontline therapy for bladder cancer and other solid tumors.
Read more →AURAAura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Elisabet de los Pinos will present on September 10, 2025. The event aims to showcase the company's innovative therapies for solid tumors, particularly its lead candidate, bel-sar (AU-011). A live webcast will be available for interested parties.
Read more →AURAAura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported its financial results for Q2 2025, highlighting successful equity financing of $75 million, which will support operations into mid-2027. The company is actively enrolling patients in its global Phase 3 CoMpass trial for early choroidal melanoma and a Phase 1b/2 trial for non-muscle invasive bladder cancer. Despite the positive developments, Aura reported a net loss of $27 million, up from the previous year, reflecting increased research and development costs. The firm also filed a patent application for a new formulation of its lead candidate, bel-sar, designed to improve treatment administration in urologic oncology.
Read more →About Aura Biosciences, Inc.
Headquarters80 GUEST STREET, BOSTON, MA, 02135
Founded2007
BIOPHARMAWATCH ELITE PLUS
Trade the next AURA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime